Norverapamil is the N-demethylated metabolite of verapamil , an L-type calcium channel blocker and P-glycoprotein inhibitor. It is the major active metabolite of verapamil with approximately 20% efficacy of its parent with regard to vasodilatory activity.1 Norverapamil has been shown to inhibit mycobacterial efflux pumps and the expansion of M. tuberculosis-specific T cells.2
1.Tracy, T.S., Korzekwa, K.R., Gonzalez, F.J., et al.Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamilBr. J. Clin. Pharmacol.47(5)545-552(1999) 2.Abate, G., Ruminiski, P.G., Kumar, M., et al.New verapamil analogs inhibit intracellular mycobacteria without affecting the functions of Mycobacterium-specific T cellsAntimicrob. Agents Chemother.60(3)1216-1225(2015)